Technology and startups

Instead of treating tax reform as the only thing worth talking about, we should focus on why our enormous savings pool isn’t flowing to great founders.

The Sydney firm will open a US-based research institute and seek to make five to 10 business investments in the untapped peri- and post-menopause healthcare market.

Australia’s digital health sector is growing fast — but the companies building the next generation of regulated medical technologies say they are being cut off from the capital they need to survive.

Telstra’s longest serving CEO has arrived as Sharon AI’s chair with a stamp of approval, shrugging off criticisms about the firm in an interview with Capital Brief.

The proposed 10-year RDTI cap misunderstands the long commercialisation timelines behind biotechnology and medical technology.

Gilmour Space, Myriota and Quantum Brilliance are among the startups calling on the government to carve out priority industries from unexpected funding cuts detailed in the budget.

Deep tech firms can spend decades on R&D before earning revenue. These companies argue the proposed tax incentive age cap could cut them off mid-flight.

The Tesla chair conducted a sweeping review of Australia’s R&D incentives. But even she didn’t expect the change in last week’s budget that has blindsided the biotech and deep tech sectors.

The ASX-listed video game company cost buyers of its non-fungible tokens upwards of $8m when it scrapped its latest project.

Chief executive Will Lopes says consolidation across the fragmented sports technology sector is creating fresh acquisition opportunities as his company pushes toward breakeven.

The federal budget has united startups in outrage — but as the sector heads into consultation, its fragmented demands could leave it walking away with nothing.

A slew of ASX listed biotech and critical minerals names could lose millions due to changes in R&D incentives that have sparked concerns across the wider innovation community.

A jury said Elon Musk was too late to challenge OpenAI’s for-profit turn, clearing a legal cloud as the AI boom prepares to sell itself to public investors.

A little-noticed budget measure capping the refundable R&D tax incentive at 10 years threatens to cut off Australian biotech companies at the moment they are most expensive to run.

The most influential AI research firm in Silicon Valley has quietly scrutinised Aussie neoclouds. For ASX investors, its findings will raise eyebrows.

RBA assistant governor Brad Jones told Capital Brief that new consultations and working groups will be convened to facilitate stablecoin innovation. But scaling could take up to 20 years.